A182400 Stock Overview
Manufactures and sells biological products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NKMAX CO., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,020.00 |
| 52 Week High | ₩8,205.00 |
| 52 Week Low | ₩1,550.00 |
| Beta | 1.11 |
| 1 Month Change | 0% |
| 3 Month Change | 9.54% |
| 1 Year Change | -69.53% |
| 3 Year Change | -70.07% |
| 5 Year Change | -69.39% |
| Change since IPO | -68.68% |
Recent News & Updates
Shareholder Returns
| A182400 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 0.8% |
| 1Y | -69.5% | 28.1% | -2.2% |
Return vs Industry: A182400 underperformed the KR Biotechs industry which returned 14.6% over the past year.
Return vs Market: A182400 underperformed the KR Market which returned 6.5% over the past year.
Price Volatility
| A182400 volatility | |
|---|---|
| A182400 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A182400 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A182400's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 134 | Sangwoo Park | www.nkmax.com |
NKMAX CO., Ltd. manufactures and sells biological products in South Korea. The company offers anti-cancer immunotherapy treatment that activates the immune cells in body to kill the cancer cells; natural killer cell activity test for cancer patients; NK VUE Kit, an NK cell activity test that measures IFN-gamma released from activated NK cells with small amount of blood; and NK365, a proprietary blend of vitamins, minerals, and agaricus mushroom extract for immune system. It also provides recombinant proteins and monoclonal antibodies; and NK PUPPY, a test that measures dog’s immunity.
NKMAX CO., Ltd. Fundamentals Summary
| A182400 fundamental statistics | |
|---|---|
| Market cap | ₩172.74b |
| Earnings (TTM) | ₩15.64b |
| Revenue (TTM) | ₩10.47b |
11.0x
P/E Ratio16.5x
P/S RatioIs A182400 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A182400 income statement (TTM) | |
|---|---|
| Revenue | ₩10.47b |
| Cost of Revenue | ₩3.41b |
| Gross Profit | ₩7.06b |
| Other Expenses | -₩8.58b |
| Earnings | ₩15.64b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 182.94 |
| Gross Margin | 67.40% |
| Net Profit Margin | 149.35% |
| Debt/Equity Ratio | 22.8% |
How did A182400 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/22 14:44 |
| End of Day Share Price | 2024/03/25 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NKMAX CO., Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jinhee Kwak | Eugene Investment & Securities Co Ltd. |
| Wan Ku | NH Investment & Securities Co., Ltd. |
| Jiyong Lee | Shinhan Investment Corp. |